The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 524 KB) and Technical Notes (PDF, 756 KB) pages.



Download and Print: Download Printer-friendly PDF Download data


Table 19.26

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis
All Races, Both Sexes, 2004-2013
Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Rate Count APC Rate Count APC Rate Count APC Rate Count APC
Lymphoid Neoplasm 35.9 305,874 -0.4* 5.9 14,053 0.3 23.6 129,762 -0.6* 161.2 162,059 -0.3
1 Hodgkin Lymphoma 2.7 23,173 -1.5* 1.2 2,903 -0.5 3.2 16,148 -1.3* 4.1 4,122 -2.9*
2 Non-Hodgkin lymphoma 32.2 274,206 -0.2 4.7 11,024 0.3 19.9 110,735 -0.4* 151.7 152,447 -0.1
2(a) Non-Hodgkin lymphoma, B-cell 29.7 253,038 0.1 3.6 8,581 2.4* 18.0 100,428 -0.1 143.3 144,029 0.2
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 1.4 11,706 3.2* 2.9 6,914 2.4* 0.7 3,563 3.9* 1.2 1,229 5.8*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 26.8 228,787 -0.3 0.7 1,559 2.5* 16.6 92,753 -0.5* 133.8 134,475 -0.2
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 6.6 56,488 -1.4* 0.0 26 - 3.3 19,130 -1.2* 37.1 37,332 -1.4*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 5.8 49,480 -1.7* 0.0 23 - 2.9 16,551 -1.5* 32.7 32,906 -1.8*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 0.0 201 -4.9* - - - 0.0 56 - 0.1 142 -4.7*
2(a) 2.1.3. Mantle-cell lymphoma 0.8 6,807 1.3* 0.0 0 - 0.4 2,523 0.8 4.3 4,284 1.5*
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 0.6 5,304 -1.2* - - - 0.3 1,595 -2.4* 3.7 3,706 -0.8
2(a) 2.2.1. Lymphoplasmacytic lymphoma 0.3 2,371 -0.1 - - - 0.1 704 -1.4 1.7 1,666 0.4
2(a) 2.2.2. Waldenstrom macroglubulinemia 0.3 2,933 -2.2* - - - 0.2 891 -3.2* 2.0 2,040 -1.8*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 7.0 59,315 0.4 0.3 654 0.7 4.6 25,301 -0.2 33.2 33,360 0.7*
2(a) 2.3.1. DLBCL, NOSc 6.9 58,652 0.3 0.3 623 0.4 4.5 24,775 -0.4 33.1 33,254 0.7*
2(a) 2.3.2. Intravascular large B-cell lymphoma 0.0 89 - 0.0 0 - 0.0 40 - 0.0 49 -
2(a) 2.3.3. Primary effusion lymphoma 0.0 107 - 0.0 0 - 0.0 78 - 0.0 29 -
2(a) 2.3.4. Mediastinal large B-cell lymphoma 0.1 467 8.5* 0.0 31 - 0.1 408 8.7* 0.0 28 -
2(a) 2.4. Burkitt lymphoma/leukemia 0.4 3,464 0.1 0.3 700 4.1* 0.4 1,990 -1.2 0.8 774 0.1
2(a) 2.5. Marginal-zone lymphoma (MZL) 2.0 16,802 0.5 0.0 94 - 1.3 7,006 0.5 9.7 9,702 0.4
2(a) 2.5.1. Splenic MZL 0.2 1,480 -0.2 0.0 0 - 0.1 576 0.2 0.9 904 -0.4
2(a) 2.5.2. Extranodal MZL, MALTc type 1.2 9,999 0.9 0.0 62 - 0.8 4,473 0.8 5.4 5,464 0.9
2(a) 2.5.3. Nodal MZL 0.6 5,323 -0.2 0.0 32 - 0.3 1,957 -0.2 3.3 3,334 -0.3
2(a) 2.6. Follicular lymphoma 3.6 31,110 -2.1* 0.0 68 - 2.9 15,897 -2.5* 15.1 15,145 -1.8*
2(a) 2.7. Hairy-cell leukemia 0.3 2,582 -0.2 - - - 0.3 1,644 0.3 0.9 937 -0.9
2(a) 2.8. Plasma cell neoplasms 6.3 53,685 1.0* - - - 3.5 20,174 1.1* 33.4 33,499 1.0*
2(a) 2.8.1. Plasmacytoma 0.4 3,439 2.2* - - - 0.3 1,670 2.2* 1.7 1,759 2.1
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 5.9 50,246 1.0* - - - 3.2 18,504 1.0* 31.6 31,740 1.0*
2(a) 2.9. Heavy chain disease 0.0 37 - - - - 0.0 16 - 0.0 20 -
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 1.5 12,545 5.3* 0.0 108 - 0.7 4,112 5.1* 8.3 8,325 5.4*
2(b) Non-Hodgkin lymphoma, T-cell 2.1 18,167 0.0 0.8 1,791 0.8 1.8 9,365 -0.2 7.0 7,011 0.0
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 0.1 854 - 0.2 411 - 0.1 380 - 0.1 63 -
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 2.0 17,210 1.4* 0.6 1,377 8.7* 1.7 8,933 1.1 6.9 6,900 0.4
2(b) 2.1. Mycosis fungoides/Sezary syndrome 0.5 4,296 1.3* 0.1 122 - 0.5 2,514 0.7 1.6 1,660 1.8*
2(b) 2.1.1. Mycosis fungoides 0.5 4,157 1.2 0.1 122 - 0.5 2,470 0.6 1.5 1,565 1.7*
2(b) 2.1.2. Sezary syndrome 0.0 139 - 0.0 0 - 0.0 44 - 0.1 95 -
2(b) 2.2. Peripheral T-cell lymphoma 1.2 9,900 -0.2 0.2 399 -0.6 0.9 5,000 -0.4 4.5 4,501 0.1
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 0.4 3,550 0.8 0.0 65 - 0.3 1,689 0.9 1.8 1,796 0.7
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 0.2 1,272 1.5 - - - 0.1 492 -0.8 0.8 777 2.6
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 0.0 123 - 0.0 21 - 0.0 74 - 0.0 28 -
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 0.2 1,914 -3.2* 0.1 241 -3.1 0.2 1,082 -2.3 0.6 591 -4.3*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 0.0 84 - - - - 0.0 63 - - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 0.0 119 - 0.0 0 - 0.0 58 - 0.1 61 -
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 0.2 1,953 0.7 0.0 30 - 0.2 1,061 0.7 0.9 862 0.5
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 0.1 885 -2.2 0.0 29 - 0.1 481 -3.0 0.4 375 -1.7
2(b) 2.3. Adult T-cell leukemia/lymphoma 0.2 1,834 12.4* 0.4 830 14.4* 0.1 744 12.8* 0.3 260 4.6
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 0.1 697 2.0 0.0 24 - 0.1 476 2.5 0.2 197 2.0
2(b) 2.5. T-cell large granular lymphocytic leukemia 0.0 176 - - - - 0.0 68 - 0.1 107 -
2(b) 2.6. Prolymphocytic leukemia, T-cell 0.0 307 3.6 - - - 0.0 131 - 0.2 175 3.4*
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 0.0 103 - - - - 0.0 52 - 0.0 48 -
2(c) Non-Hodgkin lymphoma, unknown lineage 0.4 3,001 -18.4* 0.3 652 - 0.2 942 - 1.4 1,407 -
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 0.1 1,199 -22.1* 0.3 635 - 0.1 309 - 0.2 255 -
2(c) 2. Prolymphocytic leukemia, unknown lineage 0.0 95 - - - - 0.0 27 - 0.1 66 -
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 0.2 1,707 - - - - 0.1 606 - 1.1 1,086 -
2(*) 1. Total precursor lymphoma/leukemiad 1.6 13,759 -1.1* 3.4 7,960 -1.5* 0.8 4,252 -0.7 1.5 1,547 0.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 0.0 249 22.7* - - - 0.0 132 - 0.1 111 -
4 Lymphoid neoplasm, NOSc 1.0 8,246 -5.0* 0.1 120 - 0.5 2,747 -4.8* 5.3 5,379 -5.4*

Footnotes:

The APC is the Annual Percent Change over the time interval.

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Return to top

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.